Trial Profile
A Phase 1, Multicenter, Open-label, Dose-Escalation Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Marizomib (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept
- Sponsors Celgene Corporation; Triphase Accelerator Corporation
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
- 06 Dec 2016 Status changed from active, no longer recruiting to completed.
- 07 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Mar 2017.